Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.
Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria
Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and
Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i
Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, with more than 155,000 cases of NMSC reported in the UK every year.1,2 However, NMSC is significantly under-r
US retailer Costco has made a play for a bigger slice of the healthcare market by offering its members online health visits, starting from just $29, as well as other servi
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho